Chi Luu

Prof. Chi Luu

orcid

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 December 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
LALauren N. Ayton
Lauren N. Ayton
PBPeter J. Blamey
Peter J. Blamey
RGRobyn Guymer
Robyn Guymer
CLChi Luu
Chi Luu
DNDavid A. X. Nayagam
David A. X. Nayagam
FCfor the Bionic Vision Australia Research Consortium
for the Bionic Vision Australia Research Consortium
Retinal visual prostheses (“bionic eyes”) have the potential to restore vision to blind or profoundly vision-impaired patients. The medical bionic technology used to design, manufacture and implant such prostheses is still in its relative infancy, with various technologies and surgical approaches being evaluated. We hypothesised that a suprachoroidal implant location (between the sclera and choroid of the eye) would provide significant surgical and safety benefits for patients, allowing them to maintain preoperative residual vision as well as gaining prosthetic vision input from the device. This report details the first-in-human Phase 1 trial to investigate the use of retinal implants in the suprachoroidal space in three human subjects with end-stage retinitis pigmentosa. The success of the suprachoroidal surgical approach and its associated safety benefits, coupled with twelve-month post-operative efficacy data, holds promise for the field of vision restoration. Clinicaltrials.gov NCT01603576

1 December 2014 in Ophthalmology
Verified
Journal Article
Closed access
ZWZhichao Wu
Zhichao Wu
CLChi Luu
Chi Luu
LALauren N. Ayton
Lauren N. Ayton
JGJonathan K. Goh
Jonathan K. Goh
LLLucia M. Lucci
Lucia M. Lucci
RGRobyn Guymer
Robyn Guymer

1 June 2019 in Ophthalmology
Verified
Journal Article
Open access
RGRobyn Guymer
Robyn Guymer
ZWZhichao Wu
Zhichao Wu
LHLauren A.B. Hodgson
Lauren A.B. Hodgson
ECEmily Caruso
Emily Caruso
KBKate H. Brassington
Kate H. Brassington
CLChi Luu
Chi Luu
There is an urgent need for a more effective intervention to slow or prevent progression of age-related macular degeneration (AMD) from its early stages to vision-threatening late complications. Subthreshold nanosecond laser (SNL) treatment has shown promise in preclinical studies and a pilot study in intermediate AMD (iAMD) as a potential treatment. We aimed to evaluate the safety of SNL treatment in iAMD and its efficacy for slowing progression to late AMD. The Laser Intervention in Early Stages of Age-Related Macular Degeneration (LEAD) study is a 36-month, multicenter, randomized, sham-controlled trial. Two hundred ninety-two participants with bilateral large drusen and without OCT signs of atrophy. Participants were assigned randomly to receive Retinal Rejuvenation Therapy (2RT®; Ellex Pty Ltd, Adelaide, Australia) SNL or sham treatment to the study eye at 6-monthly intervals. The primary efficacy outcome was the time to development of late AMD defined by multimodal imaging (MMI). Safety was assessed by adverse events. Overall, progression to late AMD was not slowed significantly with SNL treatment compared with sham treatment (adjusted hazard ratio [HR], 0.61; 95% confidence interval [CI], 0.33-1.14; P = 0.122). However, a post hoc analysis showed evidence of effect modification based on the coexistence of reticular pseudodrusen (RPD; adjusted interaction P = 0.002), where progression was slowed for the 222 participants (76.0%) without coexistent RPD at baseline (adjusted HR, 0.23; 95% CI, 0.09-0.59; P = 0.002), whereas an increased progression rate (adjusted HR, 2.56; 95% CI, 0.80-8.18; P = 0.112) was observed for the 70 participants (24.0%) with RPD with SNL treatment. Differences between the groups in serious adverse events were not significant. In participants with iAMD without MMI-detected signs of late AMD, no significant difference in the overall progression rate to late AMD between those receiving SNL and sham treatment were observed. However, SNL treatment may have a role in slowing progression for those without coexistent RPD and may be inappropriate in those with RPD, warranting caution when considering treatment in clinical phenotypes with RPD. Our findings provide compelling evidence for further trials of the 2RT® laser, but they should not be extrapolated to other short-pulse lasers.

1 May 2016 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
BWBernice H. Wong
Bernice H. Wong
JCJia Pei Chan
Jia Pei Chan
AGAmaury Cazenave Gassiot
Amaury Cazenave Gassiot
RPRebecca W. Poh
Rebecca W. Poh
JFJuat Chin Foo
Juat Chin Foo
DSDavid L. Silver
David L. Silver
Eye photoreceptor membrane discs in outer rod segments are highly enriched in the visual pigment rhodopsin and the ω-3 fatty acid docosahexaenoic acid (DHA). The eye acquires DHA from blood, but transporters for DHA uptake across the blood-retinal barrier or retinal pigment epithelium have not been identified. Mfsd2a is a newly described sodium-dependent lysophosphatidylcholine (LPC) symporter expressed at the blood-brain barrier that transports LPCs containing DHA and other long-chain fatty acids. LPC transport via Mfsd2a has been shown to be necessary for human brain growth. Here we demonstrate that Mfsd2a is highly expressed in retinal pigment epithelium in embryonic eye, before the development of photoreceptors, and is the primary site of Mfsd2a expression in the eye. Eyes from whole body Mfsd2a-deficient (KO) mice, but not endothelium-specific Mfsd2a-deficient mice, were DHA-deficient and had significantly reduced LPC/DHA transport in vivo. Fluorescein angiography indicated normal blood-retinal barrier function. Histological and electron microscopic analysis indicated that Mfsd2a KO mice exhibited a specific reduction in outer rod segment length, disorganized outer rod segment discs, and mislocalization of and reduction in rhodopsin early in postnatal development without loss of photoreceptors. Minor photoreceptor cell loss occurred in adult Mfsd2a KO mice, but electroretinography indicated visual function was normal. The developing eyes of Mfsd2a KO mice had activated microglia and up-regulation of lipogenic and cholesterogenic genes, likely adaptations to loss of LPC transport. These findings identify LPC transport via Mfsd2a as an important pathway for DHA uptake in eye and for development of photoreceptor membrane discs.

1 June 2014 in Ophthalmology
Verified
Journal Article
Closed access
RFRobert P. Finger
Robert P. Finger
ZWZhichao Wu
Zhichao Wu
CLChi Luu
Chi Luu
FKFrances Kearney
Frances Kearney
LALauren N. Ayton
Lauren N. Ayton
RGRobyn Guymer
Robyn Guymer

1 December 2013 in Investigative Ophthalmology & Visual Science
Verified
Journal Article
Closed access
PDF file
WFWallace S. Foulds
Wallace S. Foulds
VBVeluchamy A. Barathi
Veluchamy A. Barathi
CLChi Luu
Chi Luu
Purpose. To determine whether progressive ametropia can be induced in chicks and reversed by manipulation of the chromaticity of ambient light. Methods. One-day-old chicks were raised in red light (90% red, 10% yellow–green) or in blue light (85% blue, 15% green) with a 12 hour on/off cycle for 14 to 42 days. Refraction was determined by streak retinoscopy, and by automated infrared photoretinoscopy and ocular biometry by A-scan ultrasonography. Results. Red light induced progressive myopia (mean refraction ± SD at 28 days, −2.83 ± 0.25 diopters [D]). Progressive hyperopia was induced by blue light (mean refraction at 28 days, +4.55 ± 0.21 D). The difference in refraction between the groups was highly significant at P < 0.001. Induced myopia or hyperopia was axial as confirmed by ultrasound biometry. Myopia induced by 21 days of red light (−2.21 ± 0.21 D) was reversed to hyperopia (+2.50 ± 0.29 D) by subsequent 21 days of blue light. Hyperopia induced by 21 days of blue light (+4.21 ± 0.19 D) was reversed to myopia (−1.23 ± 0.12 D) by 21 days of red light. Conclusions. Rearing chicks in red light caused progressive myopia, while rearing in blue light caused progressive hyperopia. Light-induced myopia or hyperopia in chicks can be reversed to hyperopia or myopia, respectively, by an alteration in the chromaticity of ambient light. Manipulation of chromaticity may be applicable to the management of human childhood myopia.